Psammiad Therapeutics
Denver, US · Founded 2022 · Delaware corporation
Founders & leadership
MV
Matthew VeatchNamed on SEC filing
AG
Anthony GerberNamed on SEC filing
ME
Michael EberNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2022
▶$2.2MraisedFeb 2022 · 5 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2022 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew VeatchExecutive Officer
- Anthony GerberExecutive Officer, Director
- Michael EberExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2.2M
- Minimum investment
- $10K
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Psammiad Therapeutics raised?
- Psammiad Therapeutics has disclosed $2.2M raised across 1 round.
- Where is Psammiad Therapeutics headquartered?
- Psammiad Therapeutics is headquartered in Denver, US.